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Abstract 
Introduction: Post-operative thyroglobulin (TgPO) is a recognised prognostic factor in patients following thyroidectomy due to differ-
entiated thyroid cancer (DTC). However, its concentration is affected by thyroid remnants, which may diminish the prognostic value of 
TgPO. The aim of this paper is to assess the usefulness of stimulated post-ablative thyroglobulin (TgPA) measurements 6–9 months after 
131I therapy, as a prognostic factor, and its possible advantage over TgPO determination.
Material and methods: The study involved 577 DTC patients treated in the Holycross Cancer Centre in the years 2000–2013. Exclusion 
criteria were: patients with no recommendation for 131I adjuvant therapy, positive thyroglobulin antibody titre, and initial distant metas-
tases. On the basis of a ROC curve analysis, values of TgPO and TgPA concentrations were determined, which enable the most accurate 
identification of good prognosis. Calculating area under the curves (AUCs) allowed for comparison of the data.
Results: TgPO concentration ≤ 6.99 ng/mL, with 75.7% sensitivity and 94.7% specificity enables anticipation of remission of the disease. 
TgPA concentration ≤ 1.16 ng/mL under endogenous TSH stimulation with sensitivity of 91.1% and specificity of 94.7% allows anticipation 
of remission of the disease. TgPA concentration ≤ 1.24 ng/mL under rh TSH stimulation with sensitivity of 95.4% and specificity of 95.0% 
enables anticipation of remission of the disease. 
Conclusions: No differences in clinical usefulness of the assessment of TgPO and stimulated TgPA concentrations as indicators of good 
prognosis were found. However, TgPA allows anticipation of remission of the disease with higher sensitivity. It also appears that TgPA 
may be of particular prognostic importance in baseline high-risk patients (pT3-T4/N1). A sufficiently low TgPA concentration, demon-
strating good response to 131I adjuvant therapy in these groups, is an indicator of improved prognosis.  (Endokrynol Pol 2015; 66 (6): 486–494)
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Streszczenie
Wstęp: Tyreoglobulina pooperacyjna (TgPO) jest uznanym czynnikiem rokowniczym u pacjentów po tyreoidektomii z powodu raka 
zróżnicowanego tarczycy (DTC). Na jej stężenie wpływa jednak ilość pozostawionej tkanki tarczycowej, co może obniżać jej wartość jako 
wskaźnika prognostycznego. Celem pracy jest ocena przydatności oznaczeń stymulowanej tyreoglobuliny poablacyjnej (TgPA), ocenianej 
6–9 miesięcy po leczeniu 131I, jako czynnika rokowniczego i jej ewentualna przewaga nad oznaczeniami TgPO.
Materiał i metody: Badaniem objęto 577 pacjentów z DTC leczonych w Świętokrzyskim Centrum Onkologii w latach 2000–2013. Wyklu-
czono chorych niewymagających leczenia uzupełniającego 131I, chorych z dodatnim mianem przeciwciał przeciw tyreoglobulinie oraz 
z przerzutami odległymi obecnymi w chwili rozpoznania. Na podstawie analizy krzywych ROC, ustalono wartości stężeń TgPO i TgPA, które 
pozwalają najlepiej przewidywać dobre rokowanie. Ocena wielkości pól pod krzywymi ( AUCs) umożliwiła porównanie obu parametrów. 
Wyniki: Remisję stwierdzono u 93,2 % chorych, brak remisji u 6,8 % badanych. 
Stężenie TgPO ≤ 6,99 ng/ml z czułością 75,7% i swoistością 94,7 % pozwala przewidzieć remisję choroby. Stężenie TgPA ≤ 1,16 ng/ml na 
stymulacji endogennym TSH z czułością 91,1% i swoistością 94,7% pozwala przewidywać remisję choroby. Stężenie TgPA ≤ 1,24 ng/ml 
na stymulacji rhTSH z czułością 95,4% i swoistością 95,0% pozwala przewidywać remisję choroby. 
Wnioski: Nie wykazano różnic w przydatności klinicznej oceny stężenia TgPO i stymulowanej TgPA jako wskaźnika dobrej prognozy. 
Jednak TgPA przy stężeniu ≤ 1,24ng/ml pozwala z większą czułością przewidzieć remisję choroby. Wydaje się również, że TgPA może 
mieć szczególne znaczenie rokownicze u pacjentów z wyjściowo wysokim ryzykiem ( pT3-T4/N1). Odpowiednio niskie stężenie TgPA, 
świadczące o dobrej odpowiedzi na leczenie uzupełniające 131I w tych grupach jest wskaźnikiem poprawy rokowania. 
(Endokrynol Pol 2015; 66 (6): 486–494)
Słowa kluczowe: zróżnicowany rak tarczycy; tyreoglobulina; czynniki rokownicze; remisja
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of the disease was 100% with TgPO concentration 
< 10 ng/mL and undetectable Tg concentration during 
the suppressive treatment [12]. In a group of 243 high-
risk patients, NPV was 93% with TgPO concentration 
of <10 µg/L [10]. Heemstra et al. advocate that TgPO 
concentrations < 27.5 µg/L enable anticipation of 
a favourable course of the disease (sensitivity — 87.9%, 
specificity — 90.3%; PPV for remission — 98%) [13]. 
A study by Kim et al. demonstrated that patients with 
TgPO concentrations > 5.22 ng/mL are burdened with 
a higher risk of recurrence of the disease [14]. Klubo-
Gwiezdzinska et al. claimed TgPO < 5 ng/mL to have 
NPV = 100% in a study of 91 patients [15].
TgPO concentration values are affected by the pres-
ence of thyroid tissue remaining after surgery. It is esti-
mated that 1 g of thyroid tissue causes an increase in Tg 
concentration of approximately 1 µg/L with normal TSH 
concentration, and by approximately 0.5 µg/L during 
TSH suppression. The fact may reduce the prognostic 
usefulness of TgPO [16].
It seems that the assessment of Tg concentration fol-
lowing ablative 131I treatment (TgPA) may demonstrate 
greater prognostic value. The aim of the work was to 
assess the usefulness of measuring Tg concentration 
under exogenous or endogenous TSH stimulation as 
a prognostic factor, and its possible advantage over the 
TgPO determination.
Material and methods
The study involved 1200 DTC patients treated in 
the Holycross Cancer Centre in the years 2000–2013. 
Patients with distant metastases at the diagnosis 
and those who did not require 131 I adjuvant therapy 
were excluded from the study. Out of the remaining 
661 patients, 85 were excluded due to the presence of 
thyroglobulin antibodies. 
Eventually, the study involved 577 patients: 491 (85%) 
females and 86 (15%) males. The age median at the 
diagnosis was the same for both sexes, at 53 years 
(minimum–maximum age for women was 17–80 years, 
for men it was 23–76 years).
The dominant histological type was papillary car-
cinoma: 531 cases (92%), then follicular carcinoma — 
33 cases (5.7%), insular carcinoma — 7 cases (1.2%), and 
oxyphil carcinoma — 6 cases (1%). 
All patients underwent complete thyroidectomy 
with the intent to remove the central cervical compart-
ment lymph nodes, and later they received adjuvant 
131I treatment with 1100–3700 MBq activity, repeated 
according to indications. 
Patients having pT1N0/Nx and pT2N0 stage were 
assigned for low 131-I activity (patients with Nx feature 
were considered as low-risk on the basis of undetectable 
Introduction
Thyroglobulin (Tg) is a glycoprotein produced exclu-
sively by the follicular cells of the thyroid. The follicular 
cells modified by the neoplastic process maintain the 
ability to produce thyroglobulin in most types of dif-
ferentiated neoplasms [1].
Therefore, in patients following complete thyroid-
ectomy and 131I ablative treatment due to differentiated 
thyroid cancer (DTC), Tg is used as a neoplastic marker 
to monitor the disease [2–6]. 
Differentiated thyroid cancer (DTC) is a neoplasm 
characterised by good prognosis. Approximately 80% 
of patients recover after the first treatment. However, 
around 15% of patients are affected by local recurrence 
of the disease, and in 5–10% distant metastases occur. 
Most recurrences of the disease take place within 
the first five years; however, recurrences were also 
observed as late as after 45 years [7, 8]. Such reports 
necessitate life-long oncological monitoring of DTC 
patients.
Prognostic factors are still being sought that would 
enable the identification of patients with high risk of 
disease recurrence, allowing personalisation of the 
method of DTC management according to the patient’s 
risk group.
Recently, numerous publications have appeared 
indicating the usefulness of the assessment of thy-
roglobulin concentration following thyroid surgery 
(TgPO) as a prognostic marker. Makarewicz et al., 
using an analysis of 247 patients, demonstrated that 
TgPO > 38.1 ng/mL is strongly correlated with the 
presence of distant metastases (sensitivity — 0.57; 
specificity — 0.96) [9]. The studies by Piccardo et al. 
established that in high-risk patients TgPO concentra-
tions > 50 µ/L had the highest positive predictive value 
(PPV) — 97% for the presence of persistent disease, 
compared to factors such as age, feature T, N, G, or 
histological type of cancer [10]. The cut-off point for 
TgPO concentration, indicating favourable prognosis, 
has not been arbitrarily established. It is believed that 
in patients with lower TgPO concentration the prob-
ability of persistent or recurring disease is reduced. 
It has been concluded in a few studies that TgPO 
concentrations < 10 ng/mL indicate good prognosis. 
Polachek et al. decided, based on observations of 
420 patients, that this TgPO concentration has a nega-
tive predictive value (NPV) of 89% for persistent dis-
ease, with sensitivity and specificity of 73% [11]. The 
same cut-off point for TgPO concentration, which 
enables one to anticipate a remission, has been deter-
mined by Piccardo et al. in low-risk [12] and high-risk 
[10] patients. In a two-year observation of 169 low-risk 
patients, they established that NPV for a recurrence 
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TgPO and normal neck ultrasound). Patients who had 
pT2-4/Nx stage were assigned for high 131-I activity. 
Table I presents in detail the distribution of patients 
by pTNM classification according to IUCC/AJCC TNM 
staging system 2010.
Patients are under continuous observation with 
periodic clinical assessments. Median (Q1–Q3) for the 
follow-up period is 5 (2.0–9.0) years. At the moment 
of analysis, 538 patients (93.2%) are in remission, and 
39 patients (6.8%) were diagnosed with persistent 
disease.
Remission was determined on the basis of normal 
results of ultrasound neck examination, absence of 
radiotracer uptake foci in whole body scintigraphy, 
undetectable Tg concentration during the treatment 
with suppressive dose of l-thyroxine, and TgPA con-
centration < 1 ng/mL on recombinant human thyroid-
stimulating hormone (rh TSH) stimulation, or TgPA 
concentration < 2 ng/mL on endogenous thyroid-
stimulating hormone (TSH) stimulation.
Diagnostic imaging
Ultrasound examination of the neck was performed with 
the use of devices with colour Doppler function: Siemens 
Versa pro and Hitachi EUB-6500, EUB-5500, with a linear 
transducer 7.5 MHz. Neck and whole body scintigraphy 
was performed with the use of a Symbia T2 gamma 
camera by Siemens, following administration of 131I di-
agnostic capsule of 80 MBq activity under endogenous 
TSH stimulation, and 200 MBq with rh TSH stimulation. 
Thyroglobulin
TgPO was assessed 3–6 weeks after the thyroidectomy, 
at qualification for the adjuvant 131I treatment, prior to 
implementation of substitute treatment with l-thyroxine. 
TgPA was assessed 6–9 months after the 131I treatment, 
under endogenous TSH stimulation or rh TSH stimulation 
(Thyrogen, Genzyme Corp., amp. 0.9 mg). One ampoule 
of Thyrogen i.m. was administered on two consecutive 
days, TgPA was measured on day 5 after the adminis-
tration of the first dose. TgPO and TgPA were assessed 
with TSH ≥ 30 IU/mL ( range from ≥ 30 to > 100 IU/mL). 
During the l-thyroxine treatment, Tg was assessed every 
six months. Thyroglobulin was determined with the use 
of chemiluminescence — until 2007 on an Immulite 1 
analyser by DPC, and since 2007 on an Immulite 2000 xpi 
Immunoassay System analyser by Siemens. The method’s 
analytical sensitivity was < 0.2 ng/mL. 
Statistical analysis
For the measurable parameters tested the basic statistics 
were determined (mean, standard deviation, median, 
quartiles: first and third). For the qualitative characteris-
tics, frequencies were determined. The Mann-Whitney 
test, Kruskal-Wallis test, and chi-square test were 
also used. Correlation analysis was used for pairs of 
measurable characteristics. ROC (Receiver Operating 
Characteristic) curve analysis was performed for TgPO 
and TgPA concentrations. Calculating the area under 
the curves (AUCs) allowed for comparison of the data. 
P-values were presented for the tests used. The value of 
p < 0.05 was adapted as denoting statistically significant 
relationship, difference, or correlation. The statistical 
analyses were performed with the use of MedCalc 
Statistical Software version 13.0. 
The study was approved by the Local Bioethical 
Committee. 
Results
Remission
Among 577 study patients, in 538 (93.2%) disease remis-
sion was observed, and in the remaining 39 patients 
(6.8%) at the moment of analysis persistent disease 
was found.
Table I. Characteristics of patients with remission and 
without remission
Tabela I. Charakterystyka pacjentów z remisją i chorobą 
przetrwałą
Clinical factor Patients in 
remission  
(n = 538)
Patients without 
remission  
(n = 39)
P value
Age (years) at the 
disease onset 
Median (Q1–Q 3)
52 (42–60) 61 (50–69) 0.0021 
for Mann-Whitney test
Sex: 
Female
Male
466 (87%) 
72 (13%) 
25 (64%) 
14 (36%)
0.0003 
for chi-square test
T1
T2
T3
T4
Tx
275 (51%)
74 (14%)
140 (26%)
25 (5%)
24 (4%) 
8 (21%)
3 (8%)
22 (56%)
4 (10%)
2 (5%)
0.0005  
for chi-square test1
N0
N1
Nx
125 (23%)
59 (11%)
354 (66%)
5 (13%)
14 (36%)
20 (51%)
0.0001  
for chi-square test1
TgPO [ng/mL] 
Median (Q1–Q 3)
2.0 (0–148 29.8 (4.29–300) 0.0001  
for Mann-Whitney test
TgPA [ng/mL] 
Median (Q1–Q 3)
0.0 (0.0–20.5) 6.73 (0–105) 0.0001 
for Mann-Whitney test
Papillary
Oxyphil
Follicular
Insular
500 (92.9%) 
5 (0.9%)
30 (5.6%)
3 (0.6%)
31(79.4%)
1 (2.6%)
3 (7.7%)
4 (10.3%) 
0.0071
0.8450
0.8509
< 0.0001 
for chi-square test 
1p value corresponds to all Ts and to all Ns 
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Characteristics of patients with remission and with 
persistent disease are presented in Table I.
Patients with persistent disease or disease recurrence 
were older, more frequently they were males originally 
with a higher stage of clinical advancement T3–T4, and 
with lymph nodes metastases. The insular carcinoma type 
was associated with a higher risk of absence of remission. 
TgPO and TgPA concentrations were significantly higher 
in the patients without remission.
Detailed data of the patients without remission are 
presented in Table II.
Post-operative thyroglobulin
The analysis of TgPO concentration relationships is 
presented in Table III.
It was demonstrated that TgPO concentration 
depended on the sex of patients, and it was higher in 
males, as well as on the histological cancer type — the 
highest values were obtained in insular carcinoma. 
However, no statistically significant relationship was 
found between TgPO concentration and age at the 
onset of the disease, clinical advancement of the cancer, 
and lymph nodes condition. 
Considering further course of the disease, on the 
basis of ROC curve analysis, we established that TgPO 
concentration ≤ 6.99 ng/mL, with 75.7% sensitivity and 
specificity of 94.7% enabled us to anticipate remission 
of the disease (p < 0.001). This is shown in Figure 1.
Among 410 patients with TgPO ≤ 6.99 ng/mL, the 
absence of remission was observed in three patients, 
whereas out of 167 patients with Tg over this threshold 
remission was absent in 36 patients (p < 0.0001). 
Post-ablative thyroglobulin
TgPA was assessed under endogenous thyroid-stim-
ulating hormone (TSH) stimulation in 254 patients, 
and under recombinant human thyroid-stimulating 
hormone (rh TSH) stimulation in 323 patients. 
Mean (SD) TgPA concentration under endogenous 
TSH stimulation was 1.98 (9.62) ng/mL. Mean (SD) TgPA 
concentration under rh TSH stimulation was 1.57 (8.15) 
ng/mL. The observed difference was statistically non-
significant. Median stimulated TgPA concentrations in 
both groups were zero. 
The analysis of TgPA concentration relationships is 
presented in Table IV.
It was demonstrated that stimulated TgPA concen-
tration depended on the sex of patients and was higher 
in males. No statistically significant relationship was 
found between stimulated TgPA concentrations and 
age at the disease onset. 
The median for papillary carcinoma, follicular carci-
noma, and oxyphil carcinoma was zero, and for insular 
carcinoma it was 1.91 ng/mL. A statistically significant 
difference was observed in median TgPA concentrations 
(calculated in total for endogenous TSH and rh TSH 
stimulation) between individual histological types of 
carcinoma (papillary and insular carcinoma). In T1 and 
T3 groups a statistically significant relationship between 
TgPA and N1/N0 feature was observed. This was prob-
ably due to a larger number of patients in these groups 
compared to groups T2 and T4. 
On the basis of ROC curve analysis we established 
that TgPA concentration ≤ 1.16 ng/mL under endog-
enous TSH stimulation with a sensitivity of 91.1% and 
specificity of 94.7% enabled us to anticipate remission 
of the disease. (p < 0.001). This is shown in Figure 2.
Among 215 patients with TgPA ≤ 1.16 ng/mL for en-
dogenous TSH, remission did not occur in one patient, 
whereas out of 39 patients with TgPA > 1.16 ng/mL 
the absence of remission was observed in 18 patients 
(p < 0.0001). TgPA concentration ≤ 1.24 ng/mL under rh 
TSH stimulation with sensitivity of 95.4% and specific-
ity of 95.0% enabled us to anticipate remission of the 
disease (p < 0.001). This is shown in Figure 3.
Among 290 patients with TgPA concentration under 
rh TSH stimulation ≤ 1.24 ng/mL, remission did not 
occur in one patient, whereas out of 33 patients with 
concentration > 1.24 ng/mL the absence of remission 
was observed in 19 patients (p < 0.0001). 
The difference between AUCs ( TgPO vs. TgPA) was 
0.0255 (p = 0.3133), which means the both parameters 
are of the same prognostic value. However, compared 
to TgPO, TgPA concentration demonstrates significantly 
higher sensitivity: 95.4% for rh TSH stimulation and 
91.1% for endogenous TSH stimulation (vs. 75.7% for 
TgPO) with at least the same specificity as TgPO in an-
ticipating the disease remission — as shown in Table V.
Discussion
Our study involved 577 patients with DTC. Remission 
was observed in 93.2% of patients, and absence of re-
mission in 6.8% of patients.
A similarly low percentage of patients with disease 
recurrence (9%) was reported by Toubeau et al. in 
a study on 212 patients, after the patients with distant 
metastases present at the moment of diagnosis had been 
excluded from the observation [17]. 
The median follow-up period was five years, i.e. 
the time when the risk of thyroid cancer recurrence 
is highest (18), although the disease may recur at any 
moment in the patient’s life [2, 8]. TgPO concentration 
is a prognostic factor which enables early anticipation 
of the course of the disease. The cut-off point for TgPO 
concentration, indicating favourable prognosis, has not 
been arbitrarily established. Values described in the 
literature range from ≤ 10 to ≤ 50 ng/mL.
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Table II. Characteristics of patients without remission
Tabela II. Charakterystyka pacjentów bez remisji
No. Sex Age Histopathology Absence of remission Diagnostic 
method
Time to 
recurrence
TgPA
[ng/mL]Biochemical/ 
/persistent disease
Recurrence
3 F 63 ins. Cerv. lymph nodes PET 12 months 1.91
20 F 69 pap. (+) 8.67 
23 F 43 pap. (+) 4.67
29 F 49 pap. Cerv. lymph nodes USG 36 months 2.86
62 M 58 pap. Cerv. lymph nodes USG 3 months 3.93
73 F 71 oxy. (+) 61.6
84 F 57 pap.  (+) 13 months 5.45
109 F 62 pap. (+) 17 months <0.2
124 F 29 pap. (+) 38.4
125 F 79 fol. (+) 1.29
137 F 32 pap. Cerv. lymph nodes PET 30 months 2.83
141 M 66 pap. (+) 1.20
178 F 55 pap. (+) 10.3
186 F 71 ins. Cerv. lymph nodes 
Lungs
PET 64.2
195 M 44 pap. (+) 14.9
199 M 64 pap. Cerv. lymph nodes USG 10 months 16.3
247 M 51 ins. Lungs CT 12 months 78.0
294 M 61 pap. (+) 2.97
307 F 65 pap. Cerv. lymph nodes PET 12 months 1.80
317 F 61 pap. (+) 27.8
323 F 73 pap. Cerv. lymph nodes PET 46 months 2.06
327 F 56 pap. (+) 25.7
334 F 62 pap. Lungs PET/CT 10 years < 0.2
348 F 70 pap. Cerv. lymph nodes USG 30 months 105
410 F 50 pap. (+) 8.68
428 F 53 pap. (+) 18.4
435 M 75 pap. (+) 7.71
445 F 40 fol. (+) 1.27
461 M 29 pap. (+) 4.32
463 M 55 pap. (+) 1.44
467 M 34 pap. Cerv. lymph nodes USG 6 months 80.5
477 M 68 ins. Lungs CT 5 years 32.6
487 M 64 pap. (+) 6.73
520 F 27 pap. (+) 70.4
540 M 72 fol. (+) 5.45
550 F 72 pap. Cerv. lymph nodes USG 6 months 41.5 
553 M 57 pap. Lungs CT 36 months 36.9
558 F 53 pap. (+) 3.00 
562 F 75 pap. (+) 1.60 
pap. — papillary carcinoma; fol. — follicular carcinoma; oxy. — oxyphil carcinoma; ins. — insular carcinoma; Cerv. lymph nodes — cervical lymph nodes,  
PET — 18-FDG tracer
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In our study, we established, on the basis of ROC 
curve analysis, that TgPO concentration ≤ 6.99 ng/mL 
enabled us to anticipate remission of the disease with 
the highest sensitivity and specificity. However, TgPO 
determination has its limitations. First, its concentration 
is affected by the thyroid tissue remaining after thyroid-
ectomy. Webb et al., on the basis of a meta-analysis of 
nearly 4000 DTC patients, determined that PPV for the 
disease recurrence with TgPO concentration > 10 ng/mL 
is only 47%, which they associated primarily with the 
thyroid tissue remaining after the surgery [19].
Moreover, low TgPO concentration does not always 
guarantee favourable prognosis. Usually, undetectable 
TgPO concentration indicates completeness of the sur-
gical procedure. However, there are reports of patients 
who, despite undetectable TgPO (in the absence of 
Tg antibodies), developed a recurrence or persistent 
disease. In a study by Phan HT et al. such a course of 
the disease was observed in 8.5% (8/94) of patients with 
undetectable TgPO concentration. During a follow-up, 
in a few patients a detectable Tg concentration or Tg 
antibodies occurred. The authors explain it not only by 
imperfect methodology of Tg determination, but also 
by possible changes in the neoplasm properties. In their 
opinion, the frequency of the disease recurrences is the 
same in the group of patients with detectable and un-
detectable TgPO, and they emphasise the usefulness of 
Tg and Tg antibodies determination in the monitoring 
of DTC patients, despite an undetectable TgPO [20, 21]. 
Therefore, we decided to assess the usefulness of 
stimulated TgPA determination as a prognostic factor, 
and demonstrate its possible advantage over TgPO 
measurements. 
It is suggested that the cut-off point for rh TSH-stim-
ulated TgPA should be lower compared to endogenous 
TSH-stimulated TgPA [12], because higher sensitivity and 
specificity are ascribed to TgPA stimulated by endogenous 
TSH. It is associated with the fact that Tg concentration 
increases together with prolonged time of TSH stimula-
tion, and the time is longer in the case of hypothyroidism 
caused by endogenous TSH than in the case of rh TSH 
without inducing hypothyroidism [16, 22].
In a meta-analysis comprising over 9000 patients, Eu-
statia-Rutten C. F et al. established the highest sensitivity 
and specificity of TgPA stimulated with endogenous TSH, 
comparable sensitivity but lower specificity of TgPA stimu-
lated with rh TSH, and in patients who did not undergo 
ablation the Tg specificity was significantly lower [23].
However, we believe that the diagnostic accuracy of 
both measurements is comparable [24–28].
In the results obtained in our study, the stimulated 
TgPA concentration which best correlated with the 
disease remission did not depend on the type of TSH 
stimulation, and it was ≤ 1.24 ng/mL for rh TSH and 
Table III. Analysis of relationships between mean or median TgPO concentrations and sex, histological type of the cancer, 
and TN feature
Tabela III. Analiza zależności średniego  stężenia oraz mediany stężenia TgPO w stosunku do płci, typu histologicznego raka 
i cechy TN
Clinical 
factor
Values 
of clinical factors
TgPO [ng/mL] p value1
Number of patients Mean (SD) Median (Q1–Q3)
Sex F 491 9.4 (24.9) 2.00 (0–7.5) < 0.0001
M 86 17.5 (47.6) 5.21 (1.8–11.7)
Histological 
type
Papillary carcinoma 531 8.5 (20.0) 2.2 (0.3–7.5) 0.00042 
Follicular carcinoma 33 20.1 (41.4) 8.4 (1.8–16.2)
Insular carcinoma 7 111.7 (135.3) 29.8 (5.4–254.8)
Oxyphil carcinoma 6 33.60 (66.7) 2.0 (2–27.6)
pTN N0 N1 Nx
Number  
of patients
Mean  
(SD)
Median 
(Q1–Q3)
Number  
of patients
Mean  
(SD)
Median  
(Q1–Q3)
Number  
of patients
Mean  
(SD)
Median 
(Q1–Q3)
T1 68 7.5  
(15.2)
1.4 
(0.5–7.1)
23 6.8  
(7.2)
5.6  
(1.1–8.9)
192 7.7  
(17.5)
2.22 
(0–8.2)
0.38383
T2 11 12.1 
(26.1)
2.4 
(0.5–10.8)
9 16.7  
(21.3)
7.2  
(0.5–33.5)
57 3.8  
(5.6)
1.9  
(0–5.2)
0.17953
T3 45 3.9  
(6.1)
2.1  
(0.2–6.2)
34 18.6  
(52.5)
2.3  
(0.3–17.5)
83 19.4  
(48.9)
3.1 
(0.8–13.5)
0.09253
T4 5 7.8  
(13.2)
0.4 
(0.3–13.3)
6 17.9  
(27.8)
9.1  
(1–14.5)
18 15.3  
(25.2)
0.6 
(0–28.5)
0.36683
1p value for median values for Kruskal-Wallis test; 2p value corresponds to papillary and insular carcinoma; 3p value corresponds to all Ns
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Figure 1. ROC curve for TgPO regarding remission
Rycina 1. Krzywa ROC dla TgPO w odniesieniu do remisji
Table IV. Analysis of relationships between mean and median stimulated TgPA concentrations (together for endogenous TSH 
and rh TSH) and sex, histological type of the cancer, and TN feature
Tabela IV. Analiza zależności średniego stężenia oraz mediany stężenia stymulowanej TgPA (łącznie dla endogennego TSH 
i rh TSH)  w stosunku do płci, typu histologicznego raka, cechy TN
Clinical 
factor
Values 
of clinical factors
TgPA [ng/mL] p value1
Number of patients Mean (SD) Median (Q1–Q3)
Sex F 491 1.3 (7.8) 0 (0–0) 0.0016
M 86 4.1 (13.1) 0 (0–1.7)
Histological 
type
Papillary carcinoma 531 1.3 (7.5) 0 (0–0.2) 0.00212 
Follicular carcinoma 33 1.6 (4.3) 0 (0–1.3)
Insular carcinoma 7 25.3 (33.6) 1.9 (0.2–56.3)
Oxyphil carcinoma 6 10.4 (25.1) 0 (0–0.5)
pTN N0 N1 Nx
Number  
of patients
Mean  
(SD)
Median 
(Q1–Q3)
Number  
of patients
Mean  
(SD)
Median  
(Q1–Q3)
Number  
of patients
Mean  
(SD)
Median 
(Q1–Q3)
T1 68 0.5  
(2.3)
0  
(0–0)
23 1.9  
(4.5)
0  
(0–1.0)
192 0.6  
(3.3)
0  
(0–0)
0.04483
T2 11 0.6  
(1.1)
0  
(0–0.9)
9 20.7  
(32.9)
0.6  
(0–42.1)
57 0.5  
(1.9)
0  
(0–0)
0.85053
T3 45 0.5  
(1.9)
0  
(0–0.0)
34 3.2  
(8.7)
0  
(0–1.6)
83 4.4  
(16.1)
0  
(0–1.0)
0.04393
T4 5 0.4  
(0.5)
0  
(0–0.9)
6 0.5  
(0.8)
0  
(0–1.3)
18 1.8  
(6.0)
0  
(0–0.5)
0.32743
1p value for median values for Kruskal-Wallis test; 2p value corresponds to papillary and insular carcinoma; 3p value corresponds to all Ns
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Figure 2. ROC curve for TgPA under endogenous TSH 
stimulation regarding remission
Rycina 2. Krzywa ROC dla TgPA na stymulacji endogennym 
TSH w odniesieniu do remisji
≤ 1.16 ng/mL for endogenous TSH. Compared to TgPO, 
TgPA concentration demonstrates significantly higher 
sensitivity: 95.4% for rh TSH stimulation and 91.1% for 
endogenous TSH stimulation (vs. 75.7% for TgPO) with 
at least the same specificity as TgPO in anticipating the 
disease remission. TgPA concentration is, therefore, as 
equally a significant prognostic factor as TgPO con-
centration [18]. 
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In a study based on an analysis of 715 patients with 
median follow-up of 6.2 years, Brassard M. et al. arrived 
at a very similar cut-off point for TgPA (stimulated with 
endogenous or rh TSH) = 1.4 ng/mL, indicating favour-
able prognosis with the sensitivity of 78%, specificity of 
90%, and NPV of 99% [29].
On the basis of a study involving 212 patients with 
median follow-up of five years, Toubeau et al. evalu-
ated TgPA to be the most important (similarly to lymph 
node invasion) prognostic factor in DTC (with the value 
of ≤ 10 ng/mL). TgPO (≤ 30 ng/mL) was also reliable, 
although less significant [17]. 
Also Pelttari et al. in their 16-year observation of 495 
low-risk patients (TNM I-II) emphasise the importance 
of TgPA and N1 feature as the only independent predic-
tors of the disease recurrence [30]. 
A study by Molinaro et al. established that in pa-
tients with TgPA < 5.4 ng/mL, with time a spontaneous 
recovery occurred, despite a non-optimal response to 
131I ablative treatment. Simultaneously, the authors 
emphasised the possibly important significance of TgPA 
determination for prognosis [31]. 
Moreover, in our study we were researching the rela-
tionship between Tg concentration and the histopatho-
logical type of thyroid cancer. We observed statistically 
significantly higher TgPO concentrations in the follicular 
carcinoma than in the papillary carcinoma. Insular carci-
noma was distinguished by a high TgPO concentration, as 
this type of cancer, despite a small number of patients [7], 
obtained the highest values and statistically significantly 
differed in that respect from papillary carcinoma. TgPA 
was also statistically significantly different between the 
papillary and insular carcinomas. 
Among seven patients with insular carcinoma 
there were five females and two males. Remission was 
achieved in three female patients with pT2N0/pT2Nx 
advancement stage and a maximum TgPO concentra-
tion of 7.48 ng/mL, and TgPA concentrations undetect-
able in two cases and equal to 0.60 ng/mL in one patient. 
The patients who did not achieve remission included 
two males and two females with baseline advancement 
stages pT3 and pT2N1. In one case TgPO was 29 ng/mL, 
and in the remaining cases — 149, 290, and > 300 ng/mL 
(TgPA of 32.6; 1.91; 64.2; 78 ng/mL, respectively). Three 
patients developed metastases to the lungs, and in one 
patient metastases to the paratracheal lymph nodes 
were identified on the basis of a PET examination.
Remission did not occur in the patients who did not 
demonstrate sufficient response to the 131I treatment, 
and the TgPA concentration — except for one patient 
(TgPA — 1.91 ng/mL) in whom it still remained signifi-
cantly increased. 
In our study we also assessed the relationship be-
tween TgPO or TgPA and the pTN stage. We did not 
observe a statistically significant difference in TgPO 
between the high-risk and low-risk groups, which is 
probably due to a large percentage of patients with 
the Nx feature. However, we observed higher TgPA 
concentrations in the patients with invaded lymph 
nodes in the T1 and T3 groups. The absence of a similar 
observation in the T2 and T4 groups is probably caused 
by a lower number of patients in these groups, as well 
as by the frequent presence of the Nx feature.
However, it appears that TgPA may be of particular 
prognostic importance in baseline high-risk patients 
(pT3-T4/N1). Sufficiently low TgPA concentration, 
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Figure 3. ROC curve for TgPA under rh TSH stimilation 
regarding remission
Rycina 3. Krzywa ROC dla TgPA na stymulacji rh TSH 
w odniesieniu do remisji
Table V. Comparison of sensitivity and specificity of TgPO 
and TgPA in predicting remission. Tg criteria for remission 
established on the basis of ROC curve analysis
Tabela V. Porównanie czułości i swoistości TgPO i TgPA 
w odniesieniu do remisji. Punkt odcięcia stężenia Tg ustalony 
w oparciu o analizę krzywych ROC
Tg Sensitivity (%) Specificity (%) Criterion [ng/mL]
TgPO 75.7 94.7 ≤ 6.99
TgPA
under 
endogenous 
TSH 
stimulation
91.1 94.7 ≤ 1.16
TgPA
under rhTSH 
stimulation
95.4 95.0 ≤ 1.24
494
PR
A
C
E 
O
RY
G
IN
A
LN
E
Comparison of TgPO and TgPA in DTC patients Klaudia Gadawska-Juszczyk, Aldona Kowalska
demonstrating good response to 131I adjuvant therapy 
in these groups, is an indicator of improved prognosis. 
Prognosis becomes comparable to that assumed for the 
patients with lower advancement stage at the baseline 
(pT1-T2) [17].
On the basis of the analysis of patients with insular 
carcinoma, it also seems that the concentration of stimu-
lated TgPA in DTC cases with biologically higher ma-
lignancy potential, and maintained ability to produce 
Tg, may be an indicator of the course of the disease. 
Conclusions 
No differences in clinical usefulness of the assessment of 
TgPO and stimulated TgPA concentrations as indicators 
of good prognosis were found. However, stimulated 
TgPA at a concentration ≤ 1.24 ng/mL enabled us to 
anticipate remission of the disease with significantly 
higher sensitivity than TgPO. No significant difference 
in TgPA concentrations depending on the type of stimu-
lation (endogenous TSH and rh TSH) was observed. 
It seems that stimulated TgPA may demonstrate 
a higher diagnostic value than TgPO in patients with 
more advanced stages of DTC (pT3-T4), as well as in 
histologically less differentiated cancers (insular carci-
noma), i.e. cancers with higher malignancy potential 
and maintained ability to produce Tg. A sufficiently 
low concentration of stimulated TgPA indicates a good 
response to the 131I ablative treatment, and a better 
prognosis. However, this still needs to be determined 
unambiguously in further investigation. 
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